Thermo Fisher Scientific to Acquire Patheon

On May 15, 2017, Thermo Fisher Scientific announced plans to purchase Patheon for $35 per share in cash. The transaction totals approximately $7.2 billion, which includes the assumption of approximately $2 billion of net debt.

Patheon has a network of facilities, primarily in North America and Europe, and approximately 9000 professionals worldwide. In 2016, Patheon generated approximately $1.9 billion in revenue and will become part of Thermo Fisher's Laboratory Products and Services Segment, the companies said in a press release about the acquisition. The transaction is expected to be completed by the end of 2017.

“The combined company's extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities,” the companies noted in a statement. “For example, having biologics development and manufacturing capabilities as well as bioproduction technologies in one company will allow Thermo Fisher to offer a more comprehensive portfolio to gain share with these customers.”